Type I Interferons are essential for the efficacy of replicase-based DNA vaccines

Vaccine

Volumn 24, Issue 24, 2006, Pages 5110-5118

  Leitner, Wolfgang W ^a   Bergmann Leitner, Elke S ^b   Hwang, Leroy N ^a   Restifo, Nicholas P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Alphavirus; DNA vaccines; Tumor therapy; Type I IFN

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; BETA INTERFERON; BETA INTERFERON RECEPTOR; CANCER VACCINE; DNA VACCINE; IMMUNOLOGICAL ADJUVANT; INTERFERON; PLASMID DNA; RNA DIRECTED RNA POLYMERASE; TYROSINASE RELATED PROTEIN 1;

ALPHA VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA TRANSFECTION; DRUG EFFICACY; HUMORAL IMMUNITY; IMMUNOGENICITY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ALPHAVIRUS; ANIMALS; IMMUNIZATION; INTERFERON TYPE I; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; OXIDOREDUCTASES; PLASMIDS; REPLICON; VACCINES, DNA;

EID: 33744510033     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.04.059     Document Type: Article

References (51)

1. Leitner W.W., Ying H., and Restifo N.P. DNA and RNA-based vaccines: principles, progress and prospects. Vaccine 18 9-10 (1999) 765-777
2. Zhou X., Berglund P., Rhodes G., Parker S.E., Jondal M., and Liljestrom P. Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine 12 16 (1994) 1510-1514
3. Hariharan M.J., Driver D.A., Townsend K., Brumm D., Polo J.M., Belli B.A., et al. DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J Virol 72 2 (1998) 950-958
4. Driver D.A., Polo J.M., Belli B.A., Banks T.A., Hariharan M.J., and Dubensky T.W. Plasmid DNA-based alphavirus expression vectors for nucleic acid immunization. Curr Res Mol Ther 1 (1998) 510-517
5. Tubulekas I., Berglund P., Fleeton M., and Liljestrom P. Alphavirus expression vectors and their use as recombinant vaccines: a minireview. Gene 190 1 (1997) 191-195
6. Leitner W.W., Ying H., Driver D.A., Dubensky T.W., and Restifo N.P. Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res 60 1 (2000) 51-55
7. He B. Viruses, endoplasmic reticulum stress, and interferon responses. Cell Death Differ (2006)
8. Kawai T., and Akira S. Innate immune recognition of viral infection. Nat Immunol 7 2 (2006) 131-137
9. Leitner W.W., Hwang L.N., De Veer M.J., Zhou A., Silverman R.H., Williams B.R., et al. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med 9 1 (2003) 33-39
10. Leitner W.W., Hwang L.N., Bergmann-Leitner E.S., Finkelstein S.E., Frank S., and Restifo N.P. Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines. Vaccine 22 11-12 (2004) 1537-1544
11. Ying H., Zaks T., Wang R.F., Irvine K.R., Kammula U., Marincola F.M., et al. Cancer therapy using a self-replicating RNA vaccine. Nat Med 5 7 (1999) 823-827
12. Asselin-Paturel C., and Trinchieri G. Production of type I interferons: plasmacytoid dendritic cells and beyond. J Exp Med 202 4 (2005) 461-465
13. Tough D.F. Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation. Leuk Lymphoma 45 2 (2004) 257-264
14. Trinchieri G., Peritt D., and Gerosa F. Acute induction and priming for cytokine production in lymphocytes. Cytokine Growth Factor Rev 7 2 (1996) 123-132
15. Alexopoulou L., Holt A.C., Medzhitov R., and Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413 6857 (2001) 732-738
16. Diebold S.S., Montoya M., Unger H., Alexopoulou L., Roy P., Haswell L.E., et al. Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature 424 6946 (2003) 324-328
17. Bogdan C., Mattner J., and Schleicher U. The role of type I interferons in non-viral infections. Immunol Rev 202 (2004) 33-48
18. Asselin-Paturel C., Brizard G., Chemin K., Boonstra A., O'Garra A., Vicari A., et al. Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J Exp Med 201 7 (2005) 1157-1167
19. Pestka S., Krause C.D., and Walter M.R. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 202 (2004) 8-32
20. Sleijfer S., Bannink M., Van Gool A.R., Kruit W.H., and Stoter G. Side effects of interferon-alpha therapy. Pharm World Sci 27 6 (2005) 423-431
21. Cull V.S., Broomfield S., Bartlett E.J., Brekalo N.L., and James C.M. Coimmunisation with type I IFN genes enhances protective immunity against cytomegalovirus and myocarditis in gB DNA-vaccinated mice. Gene Ther 9 20 (2002) 1369-1378
22. Aguet M., Grobke M., and Dreiding P. Various human interferon alpha subclasses cross-react with common receptors: their binding affinities correlate with their specific biological activities. Virology 132 1 (1984) 211-216
23. Muller U., Steinhoff U., Reis L.F., Hemmi S., Pavlovic J., Zinkernagel R.M., et al. Functional role of type I and type II interferons in antiviral defense. Science 264 5167 (1994) 1918-1921
24. Kawakami Y., Eliyahu S., Delgado C.H., Robbins P.F., Sakaguchi K., Appella E., et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91 14 (1994) 6458-6462
25. Kawakami Y., Robbins P.F., and Rosenberg S.A. Human melanoma antigens recognized by T lymphocytes. Keio J Med 45 2 (1996) 100-108
26. Carr D.J., and Noisakran S. The antiviral efficacy of the murine alpha-1 interferon transgene against ocular herpes simplex virus type 1 requires the presence of CD4(+), alpha/beta T-cell receptor-positive T lymphocytes with the capacity to produce gamma interferon. J Virol 76 18 (2002) 9398-9406
27. Surman D.R., Irvine K.R., Shulman E.P., Allweis T.M., Rosenberg S.A., and Restifo N.P. Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization. J Immunol Methods 214 1-2 (1998) 51-62
28. Wang M., Bronte V., Chen P.W., Gritz L., Panicali D., Rosenberg S.A., et al. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol 154 9 (1995) 4685-4692
29. Leitner W.W., Seguin M.C., Ballou W.R., Seitz J.P., Schultz A.M., Sheehy M.J., et al. Immune responses induced by intramuscular or gene gun injection of protective deoxyribonucleic acid vaccines that express the circumsporozoite protein from Plasmodium berghei malaria parasites. J Immunol 159 12 (1997) 6112-6119
30. Touloukian C.E., Leitner W.W., Robbins P.F., Li Y.F., Kang X., Lapointe R., et al. Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function. Cancer Res 62 18 (2002) 5144-5147
31. Overwijk W.W., Tsung A., Irvine K.R., Parkhurst M.R., Goletz T.J., Tsung K., et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 188 2 (1998) 277-286
32. Le Bon A., Schiavoni G., D'Agostino G., Gresser I., Belardelli F., and Tough D.F. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14 4 (2001) 461-470
33. Weiss R., Scheiblhofer S., Freund J., Ferreira F., Livey I., and Thalhamer J. Gene gun bombardment with gold particles displays a particular Th2-promoting signal that over-rules the Th1-inducing effect of immunostimulatory CpG motifs in DNA vaccines. Vaccine 20 25-26 (2002) 3148-3154
34. Weber L.W., Bowne W.B., Wolchok J.D., Srinivasan R., Qin J., Moroi Y., et al. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 102 6 (1998) 1258-1264
35. Bohm W., Thoma S., Leithauser F., Moller P., Schirmbeck R., and Reimann J. T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas. J Immunol 161 2 (1998) 897-908
36. Goldszmid R.S., Idoyaga J., Bravo A.I., Steinman R., Mordoh J., and Wainstok R. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. J Immunol 171 11 (2003) 5940-5947
37. Calarota S.A., and Weiner D.B. Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants. Immunol Rev 199 (2004) 84-99
38. Sin J.I., Kim J., Chattergoon M., Ayyavoo V., McCallus D., Ugen K.E., et al. Engineering of DNA vaccines using molecular adjuvant plasmids. Dev Biol (Basel) 104 (2000) 187-198
39. Zhou H., Luo Y., Lo J.F., Kaplan C.D., Mizutani M., Mizutani N., et al. DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor. Proc Natl Acad Sci USA 102 31 (2005) 10846-10851
40. van Duin D., Medzhitov R., and Shaw A.C. Triggering TLR signaling in vaccination. Trends Immunol 27 1 (2006) 49-55
41. Claassen E., de Leeuw W., de Greeve P., Hendriksen C., and Boersma W. Freund's complete adjuvant: an effective but disagreeable formula. Res Immunol 143 5 (1992) 478-483
42. Leenaars P.P., Hendriksen C.F., Angulo A.F., Koedam M.A., and Claassen E. Evaluation of several adjuvants as alternatives to the use of Freund's adjuvant in rabbits. Vet Immunol Immunopathol 40 3 (1994) 225-241
43. Brennan F.R., and Dougan G. Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies. Vaccine 23 24 (2005) 3210-3222
44. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303 5663 (2004) 1526-1529
45. Diebold S.S., Kaisho T., Hemmi H., Akira S., and Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303 5663 (2004) 1529-1531
46. Pasare C., and Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Microbes Infect 6 15 (2004) 1382-1387
47. Balachandran S., Roberts P.C., Kipperman T., Bhalla K.N., Compans R.W., Archer D.R., et al. Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/Caspase-8 death signaling pathway. J Virol 74 3 (2000) 1513-1523
48. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20 (2002) 709-760
49. Tudor D., Dubuquoy C., Gaboriau V., Lefevre F., Charley B., and Riffault S. TLR9 pathway is involved in adjuvant effects of plasmid DNA-based vaccines. Vaccine 23 10 (2005) 1258-1264
50. Gautier G., Humbert M., Deauvieau F., Scuiller M., Hiscott J., Bates E.E., et al. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J Exp Med 201 9 (2005) 1435-1446
51. Cull V.S., Tilbrook P.A., Bartlett E.J., Brekalo N.L., and James C.M. Type I interferon differential therapy for erythroleukemia: specificity of STAT activation. Blood 101 7 (2003) 2727-2735